<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100818">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903759</url>
  </required_header>
  <id_info>
    <org_study_id>Sagot PHRC IR 2006</org_study_id>
    <nct_id>NCT01903759</nct_id>
  </id_info>
  <brief_title>Kinetics of Inflammation Markers in Maternal Plasma: Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes</brief_title>
  <official_title>Kinetics of Inflammation Markers in Maternal Plasma (Interleukins, Matrix Metalloproteinases -MMP): Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes (SPROM) Before 34 Weeks of Amenorrhea (WA) With no Modification in the Usual Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to help obstetricians to diagnose chorioamniotic
      infection early, in cases of premature rupture of the fetal membranes before 34 WA, by
      proposing earlier and more specific markers of infection than FBC and CRP. The aim is to
      reduce vital and functional risk of acute chorioamnionitis for the mother, the fetus or the
      newborn,.

      If the kinetics profile of one or several markers correlates strongly with the diagnosis of
      chorioamnionitis, it could be used in clinical practice, possibly in the context of another
      clinical study.

      The results of the study presented here are destined to be published in obstetrics journals.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>determination of plasma cytokines</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Patients With Spontaneous Rupture of the Fetal Membranes</condition>
  <arm_group>
    <arm_group_label>Patients with spontaneous rupture of the fetal membranes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Patients with spontaneous rupture of the fetal membranes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term between 24 and 34 WA

          -  Spontaneous rupture of the fetal membranes

          -  Singleton pregnancy

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Delivery within the hour following admission

          -  Hospitalisation before 24 WA or after 34 WA

          -  Hemorrhagic placenta previa or retroplacental hematoma, known auto-immune or
             inflammatory disease

          -  Infection with human immunodeficiency virus (HIV)

          -  Refusal to provide consent.

          -  Patients provided for in articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the
             Public Health Code (e.g.: minors, adults under guardianship, etc…)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 18, 2013</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chorioamnionitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Rupture, Spontaneous</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
